The group's principal activities are developing and commercialising nutraceutical and pharmaceutical products derived from nature. It conducts research and development focused on the commercialization of healthcare and pharmaceutical products derived from forest industry by-products and other plant-based products. The group is currently focuses its product development efforts on plant sterols known for their cholesterol-lowering properties and which are also essential building blocks in the production of steroid-based pharmaceutical products. It is also currently focused on three market segments; nutraceuticals, pharmaceuticals steroids and prescription pharmaceuticals. Pharmaceuticals accounted for 75% of 2001 revenues and licensing, 25%.
